PRCT Valuation

Procept Biorobotics Corp

Add to Watchlist

Advanced Chart

31.920

+0.62(1.981%)1D

PRCT Relative Valuation

PRCT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PRCT is overvalued; if below, it's undervalued.

Historical Valuation

Procept Biorobotics Corp (PRCT) is now in the Overvalued zone, suggesting that its current forward PS ratio of 31.30 is considered Overvalued compared with the five-year average of -27.72. The fair price of Procept Biorobotics Corp (PRCT) is between 16.85 to 29.60 according to relative valuation methord. Compared to the current price of 31.92 USD , Procept Biorobotics Corp is Overvalued By 7.84%.

Relative Value

Fair Zone

16.85-29.60

Current Price：31.92

7.84%

Overvalued

-28.08

Trailing

Forward

-95.97

EV/EBITDA

Procept Biorobotics Corp. (PRCT) has a current EV/EBITDA of -95.97. The 5-year average EV/EBITDA is -49.68. The thresholds are as follows: Strongly Undervalued below -132.01, Undervalued between -132.01 and -90.85, Fairly Valued between -8.52 and -90.85, Overvalued between -8.52 and 32.64, and Strongly Overvalued above 32.64. The current Forward EV/EBITDA of -95.97 falls within the Undervalued range.

-21.12

EV/EBIT

Procept Biorobotics Corp. (PRCT) has a current EV/EBIT of -21.12. The 5-year average EV/EBIT is -24.43. The thresholds are as follows: Strongly Undervalued below -49.65, Undervalued between -49.65 and -37.04, Fairly Valued between -11.82 and -37.04, Overvalued between -11.82 and 0.80, and Strongly Overvalued above 0.80. The current Forward EV/EBIT of -21.12 falls within the Historic Trend Line -Fairly Valued range.

31.30

Procept Biorobotics Corp. (PRCT) has a current PS of 31.30. The 5-year average PS is 14.96. The thresholds are as follows: Strongly Undervalued below -0.67, Undervalued between -0.67 and 7.14, Fairly Valued between 22.77 and 7.14, Overvalued between 22.77 and 30.59, and Strongly Overvalued above 30.59. The current Forward PS of 31.30 falls within the Strongly Overvalued range.

0.00

P/OCF

Procept Biorobotics Corp. (PRCT) has a current P/OCF of 0.00. The 5-year average P/OCF is -18.34. The thresholds are as follows: Strongly Undervalued below -48.26, Undervalued between -48.26 and -33.30, Fairly Valued between -3.38 and -33.30, Overvalued between -3.38 and 11.58, and Strongly Overvalued above 11.58. The current Forward P/OCF of 0.00 falls within the Overvalued range.

-77.58

P/FCF

Procept Biorobotics Corp. (PRCT) has a current P/FCF of -77.58. The 5-year average P/FCF is -36.55. The thresholds are as follows: Strongly Undervalued below -82.65, Undervalued between -82.65 and -59.60, Fairly Valued between -13.49 and -59.60, Overvalued between -13.49 and 9.56, and Strongly Overvalued above 9.56. The current Forward P/FCF of -77.58 falls within the Undervalued range.

Procept Biorobotics Corp (PRCT) has a current Price-to-Book (P/B) ratio of 4.60. Compared to its 3-year average P/B ratio of 9.98 , the current P/B ratio is approximately -53.92% higher. Relative to its 5-year average P/B ratio of 8.82, the current P/B ratio is about -47.86% higher. Procept Biorobotics Corp (PRCT) has a Forward Free Cash Flow (FCF) yield of approximately -0.05%. Compared to its 3-year average FCF yield of -4.63%, the current FCF yield is approximately -99.02% lower. Relative to its 5-year average FCF yield of -4.50% , the current FCF yield is about -98.99% lower.

4.60

P/B

Median3y

9.98

Median5y

8.82

-0.05

FCF Yield

Median3y

-4.63

Median5y

-4.50

Competitors Valuation Multiple

The average P/S ratio for PRCT's competitors is 46.88, providing a benchmark for relative valuation. Procept Biorobotics Corp Corp (PRCT) exhibits a P/S ratio of 31.30, which is -33.23% above the industry average. Given its robust revenue growth of 42.76%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

PRCT.O

Procept Biorobotics Corp

LeMaitre Vascular Inc

Inspire Medical Systems Inc

81.79

10.49%

2.38B

Performance Decomposition

Market capitalization of PRCT decreased by 66.61% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 58.37M to 83.33M.

The secondary factor is the Margin Expansion, contributed -28.47%to the performance.

Overall, the performance of PRCT in the past 1 year is driven by Revenue Growth. Which is more sustainable.

42.76%

58.37M → 83.33M

Revenue Growth

-28.47%

-35.93 → -25.70

Margin Expansion

-80.90%

-108.64 → -20.75

P/E Change

-66.61%